Immunotherapies
| AQP4-IgG seropositive NMOSD N (%)* | First line N (%)† | AQP4-IgG seronegative NMOSD N (%)* | First line N (%)† | MOGAD N (%)* | First line N (%)† | |
| Azathioprine | 98 (31) | 69 (70) | 15 (34) | 10 (67) | 46 (36) | 33 (72) |
| Azathioprine and steroids | 30 (9) | 16 (53) | 2 (5) | 1 (50) | 22 (17) | 10 (45) |
| Classical multiple sclerosis | 48 (15) | 39 (81) | 15 (34) | 14 (93) | 19 (15) | 17 (89) |
| Combination therapy | 35 (11) | 4 (11) | 2 (5) | 0 (0) | 11 (9) | 0 (0) |
| Cyclophosphamide | 17 (5) | 8 (47) | 0 (0) | 0 (0) | ||
| Eculizumab | 18 (6) | 8 (44) | 0 (0) | 0 (0) | ||
| Eculizumab and other | 7 (2) | 0 (0) | 0 (0) | 0 (0) | ||
| Inebilizumab | 2 (1) | 1 (50) | 0 (0) | 1 (1) | 1 (100) | |
| Intravenous immunoglobulin | 10 (3) | 4 (40) | 0 (0) | 8 (6) | 4 (50) | |
| Methotrexate | 13 (4) | 5 (38) | 2 (5) | 0 (0) | 6 (5) | 1 (17) |
| Mycophenolate mofetil | 17 (5) | 0 (0) | 2 (5) | 0 (0) | 4 (3) | 1 (25) |
| Other | 21 (7) | 8 (38) | 2 (5) | 1 (50) | 4 (3) | 1 (25) |
| Rituximab | 218 (68) | 120 (55) | 25 (57) | 11 (44) | 58 (45) | 32 (55) |
| Rituximab and other | 40 (12) | 1 (3) | 5 (11) | 0 (0) | 17 (13) | 2 (12) |
| Rituximab and steroids | 29 (9) | 12 41) | 6 (14) | 3 (50) | 16 (12) | 7 (44) |
| Satralizumab | 7 (2) | 0 (0) | 0 (0) | 0 (0) | ||
| Satralizumab and other | 7 (2) | 0 (0) | 0 (0) | 0 (0) | ||
| Oral steroids | 34 (11) | 14 (41) | 7 (16) | 4 (57) | 18 (14) | 16 (89) |
| Tocilizumab | 17 (5) | 2 (12) | 3 (7) | 0 (0) | 5 (4) | 0 (0) |
Data presented as n (%).
*Percentage corresponds to the number of patients ever receiving the respective immunotherapy in AQP4-IgG seropositive, AQP4-IgG seronegative or patients with MOGAD.
†Percentage corresponds to how many of those received the respective immunotherapy first line.
AQP4-IgG, aquaporin-4 immunoglobulin G; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; NMOSDs, neuromyelitis optica spectrum disorders.